KLRS
Kalaris Therapeutics

112
Mkt Cap
$169.26M
Volume
15,243.00
52W High
$12.90
52W Low
$2.14
PE Ratio
-1.22
KLRS Fundamentals
Price
$9.20
Prev Close
$9.05
Open
$9.05
50D MA
$8.54
Beta
0.89
Avg. Volume
76,713.65
EPS (Annual)
-$11.73
P/B
4.04
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Increases By 60.8%
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totaling 867,767 shares, an...
MarketBeat·10d ago
News Placeholder
More News
News Placeholder
Kalaris Therapeutics (NASDAQ:KLRS) Downgraded to "Sell" Rating by Wall Street Zen
Wall Street Zen lowered Kalaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·10d ago
News Placeholder
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Rating of "Moderate Buy" by Brokerages
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, MarketBeat.com reports...
MarketBeat·24d ago
News Placeholder
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Expands By 26.1%
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 503,479...
MarketBeat·1mo ago
News Placeholder
Chardan Capital Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Strong-Buy
Chardan Capital raised Kalaris Therapeutics to a "strong-buy" rating in a research note on Tuesday...
MarketBeat·2mo ago
News Placeholder
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts
Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) have received an average rating of "Moderate Buy" from the five analysts that are presently covering the firm, MarketBeat.com...
MarketBeat·2mo ago
News Placeholder
Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen upgraded Kalaris Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·2mo ago
News Placeholder
Monday Sector Laggards: Biotechnology, Electronic Equipment & Products
In trading on Monday, biotechnology shares were relative laggards, down on the day by about 3%. Helping drag down the group were shares of Quince Therapeutics, down about 16.2% and shares of Kalaris...
Nasdaq News: Markets·2mo ago
News Placeholder
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five research firms that are covering the company, Marketbeat.com...
MarketBeat·2mo ago
News Placeholder
Leerink Partnrs Issues Pessimistic Outlook for KLRS Earnings
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Free Report) - Research analysts at Leerink Partnrs dropped their Q4 2025 EPS estimates for Kalaris Therapeutics in a report issued on Monday, November 17th...
MarketBeat·3mo ago
<
1
2
...
>

Latest KLRS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.